Published by Benjamin Chiou on 9th December 2024
(Sharecast News) - Shares in life sciences firm ValiRx plummeted on Monday after the AIM-listed firm announced plans to raise £1.57m to increase its R&D efforts as it continues the development of breast cancer treatment CytoLytix.
URL: http://www.digitallook.com/dl/news/story/34741479/...